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ABSTRACT
Disulfiram (DS), a clinically used drug to control alcoholism, has displayed 
promising anti-cancer activity against a wide range of tumors. Here, we demonstrated 
that DS/copper (Cu) complex effectively eliminated adult B-ALL cells in vitro and 
in vivo in patient-derived xenograft (PDX) humanized mouse models, reflected 
by inhibition of cell proliferation, induction of apoptosis, suppression of colony 
formation, and reduction of PDX tumor growth, while sparing normal peripheral blood 
mononuclear cells. Mechanistically, these events were associated with disruption of 
mitochondrial membrane potential and down-regulation of the anti-apoptotic proteins 
Bcl-2 and Bcl-xL. Further analysis on B-ALL patients’ clinical characteristics revealed 
that the ex vivo efficacy of DS/Cu in primary samples was significantly correlated 
to p16 gene deletion and peripheral blood WBC counts at diagnosis, while age, LDH 
level, extramedullary infiltration, status post intensive induction therapy, immune 
phenotype, risk category, and Ph chromosome had no effect. Together, these findings 
indicate that disulfiram, particularly when administrated in combination with copper, 
might represent a potential repurposing agent for treatment of adult B-ALL patients, 
including those clinically characterized by one or more adverse prognostic factors.
INTRODUCTION
Acute lymphoblastic leukaemia (ALL) is a clinically 
and biologically heterogeneous disorder [1, 2]. Despite 
the introduction of the first-line therapy, including high-
dose multi-agent combination chemotherapy (increasingly 
inspired to pediatric principles), hematopoietic stem cell 
transplantation, and new targeted therapy, which has 
significantly improved overall survival rate (approximately 
85%) of pediatric ALL patients, only about 30-40% of 
adults with ALL achieve long-term disease-free survival 
(DFS) [3–5]. Among others, severe adverse events that 
threaten the lives of adult, especially elderly, patients 
with ALL represent the major hindrances to the high-
dose multi-agent combination chemotherapy regimens. 
Therefore, new therapeutic approaches with high efficacy 
but low toxicity are urgently needed to treat adults with 
ALL, in order to improve their long-term DFS as well as 
overall survival.
Disulfiram (DS), a member of the dithiocarbamate 
family, is an FDA-approved drug that has been clinically 
used as an alcohol-abuse deterrent for more than six 
                  Research Paper
Oncotarget82201www.impactjournals.com/oncotarget
decades [6, 7]. In contrast to conventional chemotherapy 
agents, it exhibits low toxicity, while easily available and 
inexpensive. DS, as a strong metal-ion chelating agent, 
interacts with copper (Cu) to form the Ds/Cu complex with 
enhanced anti-tumor activity [8–10]. Recently, several 
studies have demonstrated that DS is highly effective 
against various types of solid tumors such as breast cancer 
[11–13], melanoma [9, 14, 15], and prostate cancer [16], 
as well as hematological malignancies, including ALL 
[17–19].
Apoptosis, known as type I programmed cell death, 
plays a critical role in development and homeostasis 
of organisms [20, 21]. There are two major apoptotic 
signaling cascades, the mitochondria-mediated 
intrinsic pathway and the death receptor-mediated 
extrinsic pathway. The former is often considered 
as the classic apoptotic pathway, which is initiated 
with mitochondrial injury (e.g., loss of mitochondrial 
membrane potential), resulting in mitochondrial outer 
membrane permeabilization (MOMP) and thus release of 
cytochrome c from mitochondria to cytoplasm where it 
forms apoptosome with Apaf-1 to cleave/activate caspase 
9, followed by cleavage/activation of the executioner 
caspase-3, ultimately inducing apoptosis [22, 23, 24].
Currently, it remains to be defined whether and by 
what mechanism(s) DS/Cu would be active against adult 
B-lineage acute lymphoblastic leukemia (B-ALL). Here 
we report that DS/Cu is significantly and selectively 
cytotoxic in vitro against human B-ALL cell lines and 
primary samples obtained from adults with B-ALL, 
particularly those carrying adverse prognostic genetic 
abnormalities (e.g., p16 deletion), as well as effective in 
vivo in B-ALL patient-derived xenografts, in association 
with activation of the intrinsic apoptotic pathway, at least 
in part, due to down-regulation of Bcl-2 and Bcl-xL.
RESULTS
DS/Cu exhibits dose-dependent cytotoxicity in 
human B-lineage acute lymphoblastic leukemia 
cell lines
First, we examined the cytotoxic effect of DS/Cu on 
two human B-ALL cell lines (i.e., Nalm6 and REH) using 
the Cell Counting Kit-8 (CCK-8). As shown in Figure 1A, 
while treatment with Cu alone had no significant effect on 
cell proliferation (inhibition rate=6.39±4.93%, t=-2.244, 
P=0.154 vs untreated control; not shown), exposure to a 
series of the indicated concentrations of DS coupled with 
0.5 μM Cu (DS/Cu) for 24 hrs significantly inhibited 
proliferation of Nalm6 cells in a dose-dependent manner 
(P<0.05 for each condition vs untreated control), with 
IC50 values of 0.18±0.08 µM. Analogous results were 
obtained in another B-ALL cell line, REH (Figure 1A; 
P<0.05 for each condition vs untreated control), with IC50 
values of 0.243±0.256 μM.
We next examined whether DS with or without 
Cu induce apoptosis in B-ALL cell lines. To this end, 
after exposed to various indicated concentrations of 
DS in the presence or absence of 0.5 μM Cu for 24 hrs, 
flow cytometric analysis with Annexin V/PI double 
staining was performed to determine the percentage of 
apoptotic cells. In both Nalm6 and REH cells, Cu (0.5 
µM) administrated alone was unable to induce apoptosis 
(P>0.05 vs untreated control; see below Figure 1D). 
However, whereas ≥0.1 μM DS alone had significant 
effects, treatment with DS at different doses (0.025, 0.05, 
0.1, 0.2 μM) in combination with 0.5 μM Cu for 24 hrs 
resulted in significantly increased apoptosis in a dose-
dependent manner in Nalm6 cells (Figure 1B; P<0.05 for 
each DS dose, DS/Cu vs either untreated control or DS 
alone). Comparable phenomena were observed in REH 
cells (Figure 1C; P<0.05 for each DS dose, except 0.025 
µM, DS/Cu vs untreated control or DS alone). In addition 
to marked increases in overall percentage of Annexin V+ 
apoptotic cells when compared DS/Cu with DS alone, 
representative flow cytometric data also demonstrated that 
whereas DS (≥ 0.1 µM) by itself predominantly induced 
early apoptosis (Annexin V+/PI−, lower/right quadrant Q3; 
Figure 1D, top panels), co-treatment (24 hrs) with DS (≥ 
0.05 µM) and Cu (0.5 µM) resulted in robust increases 
in both early and late apoptosis (Annexin V+/PI+, upper/
right quadrant Q2; Figure 1D, bottom panels). However, 
exposure to neither DS nor DS/Cu resulted in necrosis 
(Annexin V−/PI+, upper/left quadrant Q1). Taken together, 
these results indicate that whereas DS itself is active 
against B-ALL cell lines, combined administration with 
non-toxic concentrations of Cu (e.g., 0.5 µM) remarkably 
potentiates cytotoxicity of DS, primarily via induction of 
apoptosis in a dose-dependent manner.
DS/Cu preferentially induces apoptosis of 
primary adult B-ALL cells, but not normal 
PBMCs
We then tested activity of DS/Cu in primary samples 
(bone marrow mononuclear cells) obtained from adults 
with B-ALL. Clinical characteristics of these B-ALL 
patients are summarized in Table 1 (also see Supplemental 
Table S1 for details). Consistent with the anti-leukemia 
activity of DS/Cu observed in B-ALL cell lines, co-
treatment (24 hrs) with ≥ 0.05 µM DS and 0.5 µM Cu 
resulted in significant increases in apoptosis of primary 
B-ALL cells (P<0.001 vs untreated control, n=32; Figure 
2A), although the responses varied among patients. 
Regardless of the marked differences in basal levels of 
spontaneous cell death among these primary samples, 
average net increases in percentage of apoptotic cells were 
7.16% 20.14% 29.52% 36.01% for 0.025, 0.05, 0.10 and 
0.20 µM DS in combination with 0.5 µM Cu, respectively, 
while only 1.29% for Cu alone (Table 2). Of note, identical 
treatments with DS/Cu displayed minimal toxic towards 
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normal peripheral blood mononuclear cells (PBMCs) 
obtained from healthy donors of hematopoietic stem cell 
transplantation (HSCT, Figure 2B and Table 2). These 
findings argue that DS/Cu might selectively eliminate 
B-ALL cells, while sparing normal hematopoietic cells, 
in consistence with low-toxicity of DS as a safe anti-
alcoholism drug.
Cytotoxicity of DS/Cu against primary B-ALL 
cells correlates to p16 deletion and WBC count 
at diagnosis in adults with B-ALL patients
To examine whether the clinical features of adult 
B-ALL patients (Table 1 and Supplemental Table S1) 
would have any effects on anti-leukemia activity of 
DS/Cu against primary B-ALL cells, we analyzed the 
potential relationship between patients’ characteristics 
and the percentage of apoptotic cells induced by a series 
of concentrations of DS in combination with 0.5 μM Cu. 
According to the NCCN Guidelines Version 1.2015 Acute 
Lymphoblastic Leukemia, high risk is generally defined as 
having any of the following poor-risk cytogenetic factors: 
hypodiploidy (<44 chromosomes); t(v;11q23) or MLL 
rearrangements; t(9;22) or BCR-ABL gene mutations; 
or complex karyotype (≥5 chromosomal abnormalities), 
while the absence of all poor-risk factors is considered 
standard risk.
Of total 32 patients enrolled in this study, median 
age was 27.5 years (range, 15-61 years); 11 (34.4%) 
were age ≥ 35 years; median peripheral white blood cell 
Figure 1: DS/Cu displays dose-dependent cytotoxic effects on human B-ALL Nalm6 and REH cells. A. Nalm6 and REH 
cells were exposed to the indicated concentrations of DS in the presence of 0.5 μM Cu for 24 hr, after which anti-proliferative effect was 
determined by a CCK-8 kit. B, C. Nalm6 (B) and REH cells (C) were treated with a series of concentrations of DS with or without 0.5 
µM Cu for 24 hr, after which percentage of apoptotic cells was determined by flow cytometry using Annexin V/PI double staining. # or 
* P<0.05, ## or ** P<0.01, ### or *** P<0.001 vs untreated control or DS alone, respectively. D. Representative data for flow cytometric 
analysis of Annexin V/PI staining in Nalm6 cells after exposed (24 hr) to the indicated concentrations of DS with or without Cu (0.5 µM).
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(WBC) count at diagnosis was 46.30 × 109/L, (range, 
1.27-429.46 × 109/L); and 13 (40.6%) and 19 (59.4%) 
had high or standard risk diseases, respectively. As shown 
in Table 3, two-way ANOVA analysis revealed that the 
ex vivo efficacy of DS/Cu towards primary B-ALL cells 
was significantly associated with WBC count at diagnosis 
(P=0.044) and p16 gene deletion of patients (P=0.008). 
However, other clinical characteristics (e.g., age, LDH 
levels, extramedullary infiltration, status at 14th and 28th 
day post intensive induction therapy, immune phenotype, 
Table 1: Patient clinical characteristics (n=32)
Characteristic Value Number of patients %
Age, years    
 Median (range) 27.5 (15-61)   
≥35  11 34.4
<35  21 65.6
WBC(×109/L)    
 Median (range) 46.3 (1.3-429.5)   
≥30  22 68.8
<30  10 31.2
LDH    
 High  22 68.8
 Normal  10 34.4
Status of d14    
 CR  20 62.5
 NR  12 31.2
Status after induction therapy  
 CR  25 78.1
 NR  7 21.9
Extramedullary infiltration   
 Yes  24 75
 No  8 25
Immune phenotype    
 Pro-B  13 40.6
 Non-proB  19 59.4
Risk category    
 High  13 40.6
 Standard  19 59.4
Ph chromosome    
 Positive  11 34.4
 Negative  21 65.6
p16 gene deletion    
 Positive  12 42.9
 Negative  16 57.1
Abbreviations: WBC, white blood cell; LDH, lactic dehydrogenase; CR, complete remission; NR, No remission.
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risk category, Ph chromosome, etc.) did not significantly 
affect response of primary B-ALL cells to DS/Cu (P>0.05 
for each of these parameters). These results raise a 
possibility that adults with B-ALL carrying certain adverse 
prognostic genetic abnormalities (e.g., p16 gene deletion) 
might be particularly susceptible to the DS/Cu regimen.
DS/Cu suppresses colony formation of B-ALL 
cells
Clonogenic assays were carried out to investigate 
the ability of DS/Cu to induce “reproductive death” in 
B-ALL cells. As shown in Figure 3, while treatment with 
Cu (0.5 μM) had no effect (P>0.05 vs untreated control), 
treatment (6 hrs) with DS (0.05 μM) alone markedly 
reduced colony number in Nalm6 cells (P<0.01 vs 
untreated control). Of note, combined treatment with DS 
and Cu (6 hr prior to plating) almost completely abolished 
the colony-forming ability of Nalm6 cells after cultured 
for 10-14 days (P<0.01 and P<0.05 vs untreated control 
and DS alone, respectively). These results indicate that DS 
is able suppress clonogenicity of B-ALL cells, an event 
dramatically enhanced by co-administration of Cu.
DS/Cu induces loss of mitochondrial membrane 
potential and activation of the intrinsic apoptotic 
pathway, in association with down-regulation of 
Bcl-2 and Bcl-xL
To further investigate the mechanism of action for 
DS/Cu to kill B-ALL cells, mitochondrial membrane 
potential (∆Ψm) was analyzed by flow cytometry using 
the ∆Ψm probe JC-1 in both cultured B-ALL cell lines 
and primary B-ALL cells. As shown in Figure 4, treatment 
with DS in combination with Cu (0.5 μM) significantly 
reduced JC-1 up-take by Nalm6 (Figure 4A) and REH 
cells (Figure 4B; P<0.05 for DS at doses ≥ 0.05 μM, 
compared to untreated control, in both cell lines), of which 
representative data is shown in Figure 4C, consistent with 
induction of apoptosis (Figure 1B and 1C). Significantly, 
exposure (12 hrs) to DS/Cu also dose-dependently induced 
loss of ∆Ψm in primary B-ALL cells (Figure 4D, P<0.05 
for DS at doses ≥ 0.1 μM, compared to untreated control, 
n=6), isolated from the adults with B-ALL as marked 
in Supplemental Table S1. Furthermore, Western blot 
analysis revealed that whereas DS alone (24 hrs) modestly 
down-regulated the anti-apoptotic proteins Bcl-2 and 
Bcl-xL, these effects of DS was markedly enhanced in 
the presence of Cu, accompanied by increased caspase-3 
cleavage (activation) and PARP degradation (Figure 4E). 
Together, these findings suggest that DS, particularly in 
combination with Cu, acts to induce cell death of adult 
B-ALL cells primarily via activation of the intrinsic 
apoptotic pathway, at least in part, due to down-regulation 
of anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2 and 
Bxl-xL).
DS/Cu is active in vivo in patient-derived 
xenograft (PDX) models of adult B-ALL
Last, in vivo anti-leukemia efficacy of DS/Cu was 
examined in patient-derived xenograft models of NOD-
scid-IL2Rg-/- (NSI) mice, generated from the primary 
sample of an adult B-ALL patient with p16 deletion. Cu 
and DS were administered by oral gavage in the morning 
and afternoon respectively, from Monday to Friday for 
Figure 2: DS/Cu induces apoptosis in primary adult B-ALL cells but not normal PBMCs. A, B. mononuclear cells 
isolated from primary bone marrow of adults with B-ALL (A) and peripheral blood of healthy donors (B) were exposed to the indicated 
concentrations of DS with 0.5 mM Cu for 24 hr, after which flow cytometric analysis was performed to determine percentage of Annexin 
V+ cells. The patients carrying p16 gene deletion are highlighted by red symbols. Horizontal lines represent the mean and SD of the values 
obtained from 32 patients (A) and 9 healthy donors (B).
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Table 3: The relation between clinical characteristics of B-ALL patients and ex vivo cytotoxicity of DS/Cu in primary 
samples
Characteristic
DS(µM) 0 0 0.025 0.05 0.10 0.20
P- value
Cu(µM) 0 0.5 0.5 0.5 0.5 0.5
Age, years
≥35(n=11)
37.36± 
17.91
38.11± 
18.53
45.47± 
19.96
57.43± 
23.71
65± 
23.59
72.81± 
20.61  
<35(n=21) 37.35± 
17.49
39.68± 
19.81
42.71± 
17.26
57.62± 
22.31
69.88± 
18.09
74.44± 
17.06 0.744
WBC(x109/L)
≥30(n=22)
40.04± 
19.37
41.96± 
20.28
48.88± 
18.27
62.57± 
21.65
69.26± 
21.59
73.88± 
19.09  
<30(n=10) 32.82± 11.31
35.48± 
14.53
39.55± 
16.84
51.46± 
24.1
61.88± 
22.32
69.09± 
18.83 0.044*
LDH
High(n=22)
38.80± 
18.95
40.52± 
19.92
44.67± 
22.28
55.83± 
25.61
64.37± 
23.25
71.77± 
20.82  
Normal(n=10)
34.61± 
15.85
36.13± 
17.63
48.62± 
14.92
62.6± 
16.43
71.96± 
18.04
76.02± 
15.26 0.644
Status of d14
CR(n=20)
37.17± 
17.7
38.91± 
18.66
45.97± 
18.15
56.3± 
23.19
63.92± 
20.85
71.80± 
17.4
 
NR(n=12)
36.7± 
19.76
38.41± 
21.32
42.71± 
21.97
57.39± 
25.91
69.62± 
23.23
74.32± 
21.83 0.577
Status after 
induction 
therapy
CR(n=25)
40.42± 
17.46
39.88± 
17.98
46.83± 
17.52
59.63± 
22.7
67.43± 
20.67
73.94± 
18.35  
NR(n=7)
33.86± 
21.82
35.95± 
24.92
38.55± 
24.63
50.6± 
25.48
63.76± 
28.04
69.52± 
23.8 0.106
Extramedullary 
infiltration
yes(n=24)
37.42± 
16.94
38.89± 
17.84
42.24± 
18.73
55.95± 
21.15
65.73± 
22.72
73.42± 
20.39  
No(n=8)
37.7± 
21.79
39.91± 
23.69
54.41± 
17.26
63.89± 
15.05
69.78± 
19.68
72.13± 
15.78 0.542
Table 2: Effects of DS treatment with or without Cu on human primary adult B-ALL cells (n=32) and normal 
PBMCs (n=9)
DS (µM) 0 0 0.025 0.05 0.10 0.20
P- value
Cu (µM) 0 0.5 0.5 0.5 0.5 0.5
Primary  
B-ALL cells
37.36±17.49 38.65±18.68 44.52±18.84 57.50±22.87 66.88±21.68 73.37±19.20 0.000
Normal PBMCs 19.57±7.40 17.87±7.14 20.89±8.22 23.04±6.18 24.76±6.57 26.82±8.26 0.117
Primary B-ALL cells and normal PBMCs were incubated with the indicated doses of DS in the presence or absence of Cu 
for 24hr, after which percentage of apoptotic cells were assessed by flow cytometry. Values represent mean ± SD for at least 
three independent experiments.
(Continued )
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Figure 3: DS/Cu significantly abolishes the colony-forming ability of Nalm6 cells. A. Nalm6 cells were exposed to 0.05 μM 
DS with or without 0.5 μM Cu for 6 hr, after which clonogeic assay was performed as described in Methods. B. Percentage of colony-
forming units (CFU) was determined by counting colonies (≥50 cells). Values represent the mean ± SD for at least three independent 
experiments.
Characteristic
DS(µM) 0 0 0.025 0.05 0.10 0.20
P- value
Cu(µM) 0 0.5 0.5 0.5 0.5 0.5
Immune 
phenotype
Pro-B(n=13)
36.35± 
19.94
37.46± 
20.5
45.34± 
17.69
62.97± 
17.7
71.11± 
16.46
75.58± 
13.25  
Non-
proB(n=19)
38.28± 
16.86
40.30± 
18.49
45.24± 
20.12
54.49± 
26.04
63.75± 
24.73
71.4± 
22.46
0.484
Risk category
High(n=13)
39.25± 
19.75
42.03± 
20.95
45.21± 
19.13
58.6± 
19.06
69.34± 
18.59
75.11± 
17.13  
Standard(n=19) 36.29± 16.96
37.17± 
17.97
45.32± 
19.22
57.44± 
26.05
65.08± 
23.75
71.28± 
22.03 0.341
Ph 
chromosome
Positive(n=11)
41.18± 
20.94
44.19± 
21.86
44.53± 
19.95
55.84± 
19.27
66.39± 
18.74
72.48± 
17.39  
Negative(n=21)
35.56± 
16.3
36.51± 
17.4
45.67± 
18.77
59.03± 
25.23
66.93± 
23.63
73.44± 
20.39 0.994
p16 gene 
deletion
Positive(n=12)
41.41± 
15.02
45.39± 
17.63
48.56± 
17.34
61.28± 
24.65
67.27± 
26.21
73.71± 
22.52  
Negative(n=16)
30.09± 
16.49
30.37± 
16.57
38.08± 
18.07
52.57± 
23.43
65.06± 
20.38
72.04± 
18.69 0.008**
Primary B-ALL cells were exposed to the indicated concentrations of DS with or without Cu for 24hr, after which 
percentage of apoptotic cells were determined by flow cytometry. Values represent mean± SD of at least three independent 
experiments. *P<0.05, **P<0.01.
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consecutive 4 weeks. Notably, mice received DS/Cu 
displayed a substantial delay in tumor growth, manifested 
by appearance of human CD45+ cells in peripheral blood 
(PB) determined by flow cytometry in none of 5 mice, 
while 4 of 5 mice developed CD45+ lesions in the control 
group, after 5 weeks of transplantation (Figure 5A). 
Consistently, co-administration of DS/Cu remarkably 
reduced tumor burden in the B-ALL PDX models, 
reflected by significantly less human CD45+ cells in 
bone marrow (BM, Figure 5B) and spleen (SP, Figure 
5C) compared to control mice (P<0.001 for each case). 
Moreover, average weight (upper panel, 0.054±0.018 
g for the DS/Cu group vs 0.276±0.078 g for control 
group, P=0.002) and size (lower panel) of spleens in 
mice received DS/Cu treatment were markedly lower or 
smaller than those of control mice. Representative data 
for detection of human CD45+ cells in PB, BM, and SP 
of PDX mice was shown in Figure 5E. Furthermore, 
Figure 4: DS/Cu activates the mitochondria-related intrinsic apoptotic pathway in B-ALL cell lines and primary cells. 
A-D. Nalm6 (A and C, upper panels), REH (B and C, lower panels), and primary B-ALL cells (D, n=6) were exposed to the indicated doses 
of DS with 0.5 μM Cu for 12 hr, after which mitochondrial membrane potential was measured by flow cytometry using a JC-1 kit as per 
the manufacturer’s instruction. MFI, mean fluorescence intensity. E. Nalm6 cells were incubated with 0.05 μM DS +/- 0.5 μM Cu for 24 hr, 
followed by Western blot analysis to monitor expression of Bcl-2 and Bcl-xL, as well as cleavage of caspase 3 and PARP.
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Figure 5: DS/Cu is active in vivo in patient-derived xenograft model of adult B-ALL. A-C. Primary cells (1×106 mononuclear 
cells per mouse) isolated from an adult with B-ALL were intravenously injected via retro-orbital vein into NSI mice. 7 days after cell 
inoculation, mice were randomized (n=5 per group) and treated with vehicle (control group) or DS/Cu (administered by oral gavage at dose 
of 1.5 mg/kg Cu in the morning and 150 mg/kg DS in the afternoon, from Monday to Friday for consecutive 4 weeks). Percentage of human 
CD45+ (hCD45) cells in peripheral blood (PB, A), bone marrow (BM, B) and spleen (SP, C) were then determined by flow cytometry. D. 
Spleens of mice were weighted and photographed at the end of the study (5 weeks after cells inoculation). E. Representative data of flow 
cytometry for detection of human CD45+ cells in PB, BM, and SP. F. Paraffin-embedded sections of spleen, bone marrow, lung, kidney, and 
liver were stained with H&E. G. Histologic sections of bone marrow were stained for human Bcl-2 and Bcl-xL by immunohistochemistry 
(IHC). Scale bar, 100 μm.
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histopathology after 5 weeks following transplantation 
revealed a remarkable reduction in infiltration of leukemic 
cells, accompanied by well preserved normal tissue 
architecture, in the spleen, bone marrow, lung, liver, and 
kidney of the PDX mice receiving DS/Cu, compared to 
control mice (Figure 5F). Finally, immunohistochemistry 
(IHC) staining demonstrated that treatment with DS/Cu 
clearly down-regulated the expression of Bcl-2 and Bcl-xL 
in bone marrow of the PDX mice (Figure 5G), consistent 
with the in vitro observation that DS/Cu activated the 
intrinsic apoptotic pathway (Figure 4E). Together, these 
findings argue strongly that the DS/Cu regimen is highly 
active in vivo in adult B-ALL PDX models.
DISCUSSION
Evidence has been emerging on identifying new uses 
for existing drugs, termed repurposing or repositioning, as 
an accelerated way for drug development. Repositioning 
existing drugs could increase productivity of drug 
development by shortening the process from laboratory 
investigation to clinical application due to their easy 
availability and known safety or toxicity profile. DS, also 
known as Antabuse, has been approved by the Food and 
Drug Administration (FDA) for the treatment of alcohol 
abuse and dependence (alcoholism) for more than six 
decades. Recently, repositioning DS for new indications 
has attracted a lot of attention in treatment of cancer. 
The anti-cancer activity of DS, particularly in a form of 
coupling with Cu (DS/Cu), has been demonstrated in a 
variety of cancers. For example, Conticello et al. have 
reported that primary cells isolated from patients with 
various hematological malignancies, including multiple 
myeloma (MM), acute myeloid (AML) and lymphoblastic 
leukemia (ALL), were significantly sensitive to DS alone 
or in combination with Cu [19]. Consistently, the present 
studies have further validated the anti-leukemia activity 
of DS/Cu in vitro in B-ALL cell lines and especially in 
primary samples obtained adults with B-ALL. Of note, in 
vivo efficacy of DS/Cu was identified, to the best of our 
knowledge, for the first time in PDX models generated 
from tumor cells derived from an adult B-ALL patient.
In this pre-clinical setting, DS/Cu exhibited 
remarkable cytotoxicity against both B-ALL cell lines 
and primary adult B-ALL cells, while was only minimally 
toxic towards normal PBMCs obtained from healthy 
HSCT donors and cord blood, suggesting that the DS/Cu 
regimen might be able to potently and selectively eliminate 
adult B-ALL cells. The IC50 of DS in combination 
with Cu (0.5 μM) for inhibiting proliferation of Nalm6 
and REH cells was 0.18 μM and 0.24 μM, respectively, 
which are lower than the DS IC50 of 0.5 μM in a mixture 
with Cu in MM cell lines [19]. It is noteworthy that the 
anti-proliferative IC50 of 0.5 μM for both DS and Cu is 
significantly lower than the concentration achieved with 
a normal adult dose for the treatment of alcoholism and 
for Cu recommended dietary intake [19]. Thus, the doses 
of DS and Cu that were effective against B-ALL cells 
fall within these low- or non-toxic dose range of these 
agents. Indeed, while exposure to 0.05-0.2 µM DS with 
0.5 µM Cu was highly active to induce apoptosis in both 
B-ALL cell lines and primary adult B-ALL cells in a dose-
dependent manner, treatment with the identical doses 
(i.e., ≤ 0.2 µM) of DS with 0.5 µM Cu displayed only 
minor toxicity towards normal cells. Moreover, whereas 
DS administrated alone had clear effects on B-ALL cells, 
combined treatment with non-toxic doses of Cu (e.g., 
0.5 μM) dramatically enhanced activity of DS, including 
markedly increased induction of apoptosis and suppression 
of colony formation in B-ALL cells. Moreover, the latter 
also provides evidence for the capability of DS/Cu to 
impair clonogenicity of B-ALL cells. Notably, DS/Cu 
was also highly active in vivo in PDX models of adult 
B-ALL, which were developed using humanized NSI 
mouse [25, 26], including substantial delay of tumor 
growth, reduction of tumor burden, and attenuation of 
leukemic cell infiltration in multiple organs (e.g., spleen, 
bone marrow, lung, liver, and kidney). Taken together, 
these in vitro and in vivo findings argue strongly that DS, 
especially when administrated in combination with Cu, 
might represent an effective repurposing regimen for the 
treatment of adult B-ALL.
It is well established that the therapeutic response 
and prognosis of patients with ALL are significantly 
influenced by multiple risk factors, including age, WBC 
count at the time of first diagnosis, extramedullary 
infiltration, cytogenetic abnormalities, etc. [27–31] 
Moreover, high-risk diseases are associated with greater 
incidence of chemo-resistance, higher rate of relapse, and 
lower rate of survival. To this end, we further analyzed 
the relationship between clinical characteristics and anti-
tumor activity of DS/Cu in their primary samples obtained 
from 32 adults with B-ALL. Interestingly, we found 
that the ex vivo cytotoxicity of DS/Cu was significantly 
associated with peripheral WBC count at diagnosis and 
p16 gene deletion, but not other clinical features such 
as age, LDH value, extramedullary infiltration, status at 
day 14 and 28 after intensive induction therapy, immune 
phenotype, risk category, and Ph chromosome. While 
the mechanisms underlying such correlations between 
therapeutic responses to DS/Cu and WBC counts or 
p16 deletion remain to be explored in successor studies, 
these findings might provide initial evidence for future 
development of the DS/Cu regimen as personalized 
treatment of adult B-ALL.
Several mechanisms have been reported for 
induction of apoptosis by DS/Cu in cancer cells, including 
production of reactive oxygen species [10], inhibition of 
proteasome activity [11], regulation of transcription factors 
(e.g., NF-κB), and activation of the stress-related JNK 
signaling pathway [17, 18]. It has also been demonstrated 
that DS/Cu cytotoxicity may attribute to modulation of the 
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anti- and pro-apoptotic Bcl-2 family proteins in human 
glioblastoma cells, as well as ALDH-positive cancer 
stem-like cells [10] and breast cancer stem cells [12]. The 
results of the present study elucidate that DS/Cu induced 
apoptosis of B-ALL cells most likely via activation of the 
mitochondria-related intrinsic apoptotic pathway, reflected 
by loss of mitochondria membrane potential, down-
regulation of anti-apoptotic Bcl-2 family proteins (e.g., 
Bcl-2 and Bcl-xL), and following caspase-3 activation and 
PARP degradation. A similar mechanism for anti-leukemia 
activity of DS/Cu might also operate in vivo in PDX 
models of adult B-ALL, manifested by down-regulation 
of Bcl-2 and Bcl-xL after co-administration of DS/Cu. 
While the mechanisms underlying down-regulation of 
these anti-apoptotic proteins by DS/Cu remains to be 
defined, the results of the present study suggest that DS/Cu 
might primarily act to activate the mitochondria-mediated 
intrinsic apoptotic pathway, at least in part, via down-
regulation of the anti-apoptotic Bcl-2 family proteins (e.g., 
Bcl-2 and Bcl-xL).
In summary, the present study demonstrated that 
DS in combination with Cu effectively and selectively 
eradicates adult B-ALL cells, including inhibition of 
tumor cell proliferation, induction of apoptosis, impair of 
clonogenicity, and suppression of tumor growth in PDX 
models. Significantly, cytotoxicity of DS/Cu correlated to 
certain clinical adverse prognostic factors including WBC 
counts at diagnosis and p16 gene deletion. Moreover, 
anti-leukemia activity of DS/Cu was mechanistically 
associated with down-regulation of the anti-apoptotic 
Bcl-2 family members and activation of the mitochondria-
mediated intrinsic apoptotic pathway. Therefore, the 
present findings suggest that the DS/Cu regimen warrants 
further consideration in adult B-ALL, particularly certain 
clinical/genetic subsets with poor prognosis.
MATERIALS AND METHODS
Chemicals and reagents
Disulfiram (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) and copper (Sigma-Aldrich, Dorset, 
UK) were dissolved in DMSO as 5 mM stock solution 
and phosphate-buffered saline (PBS) as 100 mM stock 
solution, respectively. Both stock solutions were stored at 
-20°C and freshly diluted with culture medium before use.
Cell lines and cell culture
Nalm6 and REH cell lines were purchased from 
ATCC (Teddington, UK). Cells were cultured in RPMI-
1640 (HyClone, Thermo Scientific, Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (FBS, Gibco, 
Life Technologies, NY, USA), 100 U/ml penicillin and 
100µg/ml streptomycin (1×P/S).
Primary samples
Peripheral blood (PB) samples from healthy 
hematopoietic stem cell transplantation (HSCT) donors 
and bone marrow (BM) samples from newly diagnosed 
adult B-ALL patients were obtained at Department 
of Hematology, Nanfang Hospital, Southern Medical 
University. Informed consent was provided for research 
purposes only, approved by the Nanfang Hospital Ethics 
Review Board, in accordance with the Declaration of 
Helsinki. Clinical characteristics of the B-ALL patients 
are summarized in Table 1 and Supplemental Table S1. 
Mononuclear cells were isolated by density gradient 
centrifugation using LymphoprepTM (BD, Franklin Lakes, 
NJ, USA), washed twice with PBS, and cultured in IMDM 
(HyClone, Thermo Scientific) supplemented with 10% 
FBS (Gibco, Life Technologies), 100 U/ml penicillin and 
100µg/ml streptomycin (1×P/S).
Cell counting kit-8 (CCK-8) assay
Cytotoxicity of DS/Cu was determined using 
a CCK-8 kit (Dojindo, Kumamoto, Japan). Briefly, 
cells (5×104 cells/well) were plated into 96-well plates 
containing 100 μl of growth medium and then treated 
with designated doses of DS in combination with 0.5 µM 
Cu for 24 hrs. After treatment, CCK-8 reagents (10 µl/
well) were added and incubated for 2 hrs at 37°C in a 5% 
CO2 incubator. Finally, absorbance at 450 nm were read 
by a microplate reader (ELX800, Bio TEK, USA). All 
experiments were repeated three times and performed in 
triplicate in each experiment. The IC50 value of each cell 
line was calculated using GraphPad Prism 5.
Annexin V-APC/PI double staining assay by flow 
cytometry
Apoptosis was measured using Annexin V-APC/
PI (Ebioscience, San Diego, USA) dual staining by flow 
cytometry. Briefly, cells (2×105/well) were seeded into 24-
well plates and exposed to DS at different doses (0.025, 
0.05, 0.1, 0.2 µM) either with or without Cu (0.5 µM) 
for 24 hrs. Cells were harvested, washed twice with iced 
PBS, and double labeled with Annexin V-APC/PI for 30 
minutes at 4°C in the dark. Cells were then analyzed by 
flow cytometry using FACS C6 (BD, Oxford, UK).
Clonogenic assay
Cells (2×105/well) were seeded in 24-well plates 
and treated for 6 hrs with DS (0.05 µM) alone or in 
combination with Cu (0.5 µM). Cells were collected and 
further cultured in complete methylcellulose medium at 
a cell density of 500/well in 6-well plates for 14 days. 
Colonies consisting of at least 50 cells were counted and 
analyzed for clonogenicity.
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Analysis of mitochondrial membrane potential
Mitochondrial membrane potential (MMP, ∆Ψm) 
was determined using a JC-1 kit (Beyotime Biotechnology, 
China) as per the manufacturer’s instruction. After 
exposed to various concentrations of DS in combination 
with 0.5 µM Cu for 12 hrs, cells were collected, washed 
twice with iced PBS, resuspended in 500 µl 1× working 
JC-1 solution, and incubated for 20 min at 37°C in the 
dark. After washing twice with a JC-1 buffer solution, 
MMP were analyzed by FACS C6 (BD).
Western blot analysis
Whole cell lysates (30 μg protein/lane) was 
electrophoresed in 10% SDS- PAGE and transferred to 
a PVDF membrane (Millipore, Billerica, MA, USA). 
After blocked for 1 hr for non-specific binding in TBS-T 
with 5% non-fat milk, blots were incubated with primary 
antibodies (Bcl-2, rabbit polyclonal, 1:500; PARP, rabbit 
polyclonal, 1:500; Bcl-xL, rabbit polyclonal, 1:1000, Cell 
Signaling Technology, Inc. Herts, UK; caspase-3, rabbit 
monoclonal, 1:1000, Beyotime, China) overnight at 4°C, 
followed by secondary HRP-conjugated monoclonal 
antibody (1:10000, Cell Signaling Technology) for 1 h 
at room temperature. Blots were re-probed with β-actin 
antibody (rabbit-monoclonal, 1:1000, Cell Signaling 
Technology) to ensure equal protein loading. Blots 
were visualized on X-ray films using an enhanced 
chemiluminescence Western blotting detection kit 
(Amersham, Little Chalfont, UK).
Animal studies in patient-derived xenograft 
(PDX) models
Male NSI 6 to 8 week old mice [25, 26] were 
kindly provided by Dr. Peng Li (Guangzhou Institutes of 
Biomedicine and Health, Chinese Academy of Sciences, 
Guangzhou, China) and housed under pathogen-free 
conditions according to the animal care guidelines. 
The protocols for the animal studies were approved by 
Southern Medical University. On the day of tumor cell 
inoculation, mice received 1 Gy of total body irradiation 
at a dose rate of 325 cGy/min by parallel opposed 4 MV 
x-ray. Within 24 hrs, mice were intravenously injected 
via retro-orbital vein with 1×106 primary mononuclear 
cells isolated from adults with B-ALL. Seven days 
after transplantation of patient B-ALL cells, mice were 
randomly assigned to either control or DS/Cu group (n 
= 5 per group) and then treated respectively with either 
vehicle (PBS and 0.5% methyl cellulose/0.5% Tween 
80 in PBS) or 1.5 mg/kg/d Cu in the morning followed 
by 150 mg/kg/d DS in the afternoon by oral gavage 
from Monday to Friday for 4 consecutive weeks. Tumor 
burden of mice was monitored every 7 days by flow 
cytometry after staining peripheral blood (PB, 50-100 
µL) collected from retro-orbital vein with an anti-human-
CD45 antibody. At the end of the experiments, mice were 
euthanized, after which their spleens were photographed 
and weighed, and leukemia load (human CD45+ cells) in 
peripheral blood (PB), bone marrow (BM) and spleen was 
determined by flow cytometry after staining with anti-
human-CD45 antibody. The viscera organs (including 
BM, spleen, liver and kidney) were removed and fixed in 
10% paraformaldehyde for 24 hrs, after which paraffin-
embedded sections were prepared and subjected to H&E 
staining and immunohistochemistry (IHC) for human Bcl-
2 and Bcl-xL.
Statistical analysis
Values represent the mean ±SD for at least three 
independent experiments. Comparisons between two 
groups were analyzed using the 2-tailed Student’s t test. 
Multiple-group comparisons were performed using the 
One-way analysis of variance (ANOVA) followed by the 
Bonferroni posthoc test. Two-way ANOVA analysis was 
used to examine the relationship between various clinical 
characteristics of B-ALL patients and cytotoxicity of DS/
Cu against primary B-ALL cells. Analyses utilized IBM 
SPSS 19.0 and GraphPad Prism 5.0 software. P values < 
0.05 was considered as statistically significant.
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